Mercados españoles cerrados

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
243,78+2,03 (+0,84%)
Al cierre: 1:00PM EST
Inicia sesión para publicar un mensaje.
  • 1
    1franksinatra
    $AVXL conversation
    from private investor and Avxl blogger Peter Karol, hot off the press, a new article.
    his Conclusions:
    "In Conclusion
    $BIIB is picking and choosing studies and group of patients, and with the exclusion the fast and furious down the 6 feet down slide and at 3,285 patients much can be claimed.
    If the claim that the blinding of the study has been compromised and the fact that on qualitative and subjecive measures Aducanumab improved most the we can stipulate that the CDR-SB was affected by this.
    The improvement in MMSE scores puts in doubt the scenario of significant efficacy as applying the same criteria to Blarcamesine trial Phase2a gives 5 fold advantage over Aducanumab to Blarcamesine.
    The above point was made in face of assumed average initial MMSE score for Aducanumab of 27 point versus that of 22.5 for the Super Responders of Blarcamesine. Relatively healthy vs. Already diseased and rescued.
    Starting with almost healty subjects (MMSE scores 24 to 30) might distort the trial as the fast deteriorating patients are excluded and the duration is only 18 months. See illusration above.
    The incidence of ARIA still present vs. almost none on Blarcamesine side.
    Just another attempt to rescue the amyloid hypothesis for Alzhiemer’s on closer examination doesn’t hold water.
    The simplest expalaination of Aducanumab strategy is to remove the worst offenders and still compare to placebo arm containing those worst offenders but your claim rests on the fact that relatively healthy rest of the dosed arm do not start to deteriorate untill much later."
  • S
    Stocktargetadvisor
    $BIIB conversation
    $BIIB
    Target Raised by Canaccord Genuity Buy USD 350 » USD 393
    Upgrades Bank of America Neutral USD 230 » USD 360
    Upgraded by BMO Capital Markets Market Perform USD 280 » USD 343
    Maintains SVB Leerink Outperform USD 342 » USD 402
  • 1
    1franksinatra
    $AVXL conversation
    remember too, our product is multi purposed, a CNS artery product, multi applications, so this if anything a major understatement. Think the first penicillin. Fighting numerous strains of infections, a best analog

    $AVXL
    Watchthosestocks
    10m
    $AVXL
    Look how this compares to
    $BIIB
    ----"Statistically significant dose-dependent (p = 0.003) improvement of Episodic Memory, which has been shown to be highly correlated (70%) with the Alzheimer’s Disease Assessment Scale–Cognitive score (ADAS-Cog; r = 0.7)."

    AVXL is ready to be the first and only Alzheimer's drug in an untouched 100 billion dollar market
  • S
    Stocktargetadvisor
    $BIIB conversation
    $BIIB
    Target Lowered by Wedbush Neutral USD 281 » USD 244
    Target Lowered by Barclays Equal Weight USD 275 » USD 265
    Target Lowered by Credit Suisse Outperform USD 359 » USD 350
    Target Lowered by Oppenheimer Holdings Outperform USD 360 » USD 340
  • J
    Jerome J. M.D
    $ALXN conversation
    Can $BIIB afford to buy Alexion? They only have 4.3B cash on hand
  • T
    Toaster001
    $BIIB conversation
    If $BIIB is undervalued, then what is $SAVA?
  • A
    AIKIDO
    Thank you FDA for early approval sNDA for $OCUL , next is sNDA for $AMRN , buyout could come early too from $BIIB $GILD. $MRK and $J&J
  • D
    Dan
    $AMD conversation
    Inverse relationship between AMD strength and $MU losses not surprising. The 1 year chart is almost a perfect inversion model. A mirror image only AMD is likely over 100% to MU's 85% decline. $INTC falls in a similar pattern though not as severe. Overall, AMD is holding up well with the China matter and I expect it will continue.

    $SNAP also holding up well in the tech sector for 2019. Evan Speigel doing what it takes to mold the executive team around his vision. Elon allowing buyout talk to help the stock isn't a bad strategy. Consider $TSLA a hold at this time.

    Washington will impact pharma greatly if it chooses to - I am betting for relative status quo and remain interested in the sector. For now, $BIIB and $JNJ are my only holdings. Both long term plays on strong balance sheets.

    My friends who played energy yesterday did well. I was still sidelined and will stay here until environment stabilizes.

    Your feedback has been constructive on most matters. Thank you.

    I wish all a great Memorial Day weekend.
  • a
    americathegreat
    $PTI conversation
    Researching Alzheimer's Disease, biotechs on the front line with potential. Some takeaways, 1st the unfortunate research results, then followed by those on the front line:
    - *Mar 23, 2019 · From 1998 to 2017 there have been about 146 unsuccessful attempts at developing drugs for Alzheimer's disease, according to the Pharmaceutical Research and Manufacturers of America, or PhRMA*
    Biggest pharmas with Mixed poor or mixed Alzheimer's Disease results:
    - Feb 10, 2020: $LLY Eli Lilly Drops As Alzheimer's Drug Fails To Meet Primary Endpoint.
    - Dec 5, 2019: $BIIB, Is this Alzheimer's drug a breakthrough for millions? Company unveils mixed results.
    - Aug 2012: $PFE Pfizer, $JNJ J&J scrap Alzheimer's studies as drug fails.

    Smaller biotechs that are currently working on Alzheimer's Disease research, include in-part:
    - $SAVA Oct. 24, 2019: PTI-125 is Cassava Sciences’ lead drug candidate for Alzheimer’s disease. The drug targets both neurodegeneration and inflammatory components of Alzheimer’s disease. In a first-in-patient, Phase 2a study funded by the National Institutes of Health (NIH), treatment with PTI-125 for 28 days reduced biomarkers of Alzheimer’s pathology, neuroinflammation and neurodegeneration, consistent with years of basic research and pre-clinical data.

    - $AVXL March 1, 2019, Anavex's announcements that its drug Anavex 2-73 induces autophagy has led to a renewed interest in the stock.

    - $PTI "Since aging is accompanied by changes in cellular protein homeostasis and an increasing demand for protein degradation, aspects of protein folding, misfolding, refolding and, importantly, protein degradation need to be linked to AD pathogenesis."

    Dec 17, 2018 "The network ensures that all the proteins within a cell make it to their final destination correctly folded and functioning as they are supposed to be. When this system becomes imbalanced, it can lead to a decrease in protein quality control. These diseases are categorized as “loss-of-function” or “gain-of-toxic function.” Loss-of-function diseases include cystic fibrosis. Gain-of-toxic-function diseases include Alzheimer’s, Huntington’s disease, and Parkinson’s disease.

    "Under the terms of the Genentech deal, Proteostasis is eligible for upfront and milestone payments totaling over $100 million. They are also eligible to receive tiered royalties on any products that become commercialized out of the deal. Genentech will handle all further research and development expenses related to the program."

    ANY other biotechs of interest in age related diseases such as Alzheimer's Disease, Huntington’s disease, and Parkinson’s disease???
  • a
    ageninrussia
    SGMO

    As a reminder $SGMO is partnered with
    1. $GILD in oncology
    2. $PFE in #hemophilia #genetherapy
    3. $BIIB in #CNS #ALZHEIMERS #PARKINSONS #CTE...

    Also @mito_gene using #mtZFN to unleash #mtDNA #mitochondria enzyme defects.

    And ZFN2.0 is yet to be unleashed in gene editing

    💥💥
  • n
    nito
    $ACIU conversation
    AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease...Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company $LLY, $BIIB, $JNJ, $PFE
    LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that will be studied in neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates. This is the first significant advancement in AC Immune’s collaboration with Eli Lilly and Company (LLY).
    https://finance.yahoo.com/news/ac-immune-initiates-phase-1-110000092.html
    LAUSANNE, Switzerland, July 17, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a.
    LAUSANNE, Switzerland, July 17, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a.
    finance.yahoo.com
  • W
    Wells
    $IONS conversation
    Below Howie R posted on StockTwits, May 26th, 8:18 am:
    $IONS $BIIB “We think ASOs are the most advanced genetically based approach for targeting neurological diseases,” alzforum.org/news/conferenc...
    People who are on the forefront of applying RNA drugs for human clinical trials have all gravitated to IONS; Biogen, Novartis, GlaxoSmithKline, Roche, Bayer, Janssen (Johnson & Johnson) and many more. These companies are not blindly pouring in billions of dollars to IONS drugs, there are clear scientific reasons, they know better than us. Cranium, in his Seeking Alpha article explicitly detailed these, I've posted a number of messages on this board expounding item by item, why IONS approaches are superior.
  • D
    Dan
    $AMD conversation
    The bearish pullback on trade and Iran is waning. I sense optimistic sentiment returning and the strength of our economy being more fully embraced. Stalwarts like AMD will continue to thrive. The rapidly declining $MU and the now (surprisingly) low performing $INTC will have their reckoning soon.

    $SNAP has managed to harness optimistic view of innovation and entrepreneurial spirit this year. $TSLA has a much larger societal impact but hold as a speculative pick as many know.

    $BIIB remains a very good pick for long term hold. Immune from trade tariffs and we bought at the relative lows.

    Energy ($TVIX , $GUSH , etc.) have been painful for me. Analytics don't support outcomes and plan to sideline for a bit.

    It's a relaxing weekend. Little d eager to go for a bicycle ride. Enjoy your week ahead. I think it will be a calm and positive one for us.

    Ring a Ding Ding!!
  • A
    AIKIDO
    AMRN, let’s check the numbers HCW price target is $51 base on 6M target population, now with Reduced it/ CVD the new population target jump to 60M to 70M so , what’s gonna be Analysts price target now? Think BP $PFE $NVS $AMGN $AZN $BIIB $GILD $ABBV should partner or buyout, so many lives will be saved
  • D
    Dan
    $AMD conversation
    Proving to be the cream of sector, Dr. Su has AMD positioned to remain in the leadership role for foreseeable future. 6 month charts for $INTC and $MU difficult to watch. No disrespect to those who held INTC last year - I was one of them. Troubling fall. MU was more obvious of a concern to most in the investment community.

    $TSLA dropping again and I continue to HOLD as speculative pick. Evan Speigel remains a powerhouse of innovation at $SNAP. A remarkable 2019.

    $BIIB proving to be another winner of late and see a strong 2020 on the horizon.

    My friends continue to get beaten down at $TVIX. I remain on the sidelines of all energy picks this week. Unpredictable.

    Good luck to all and thank you for your feedback!

    Ring a Ding Ding!!
  • A
    AIKIDO
    AMRN price target next year $300 , $200B sales project in 10 years, who’s the highest bidder $PFE $AMGN $NVS $GILD $BIIB $GSK
  • n
    nito
    $ACIU conversation
    AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease SJNJ, $BIIB, $LLY, $RHHBY
    LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, is recruiting patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, known as MTAU9937A, RO7105705, in moderate Alzheimer’s disease (AD). The same antibody, RG6100 (MTAU9937A, RO7105705), also is being studied by Genentech in a separate Phase 2 trial to evaluate its efficacy and safety in patients with prodromal-to-mild Alzheimer's disease. This anti-Tau monoclonal antibody was discovered and humanized as part of AC Immune’s collaboration with Genentech.
    AC Immune has several product candidates addressing the Tau approach, including: ACI-35, an anti-pTau vaccine partnered with Janssen Pharmaceuticals, currently in a Phase 1b/2a trial, a small molecule Tau MorphomerTM, partnered with Eli Lilly and Company, that is scheduled to enter Phase 1 in 2019; and a Tau imaging agent, partnered with Life Molecular Imaging (formerly Piramal Imaging), currently in Phase 2 clinical testing.
    https://finance.yahoo.com/news/ac-immune-announces-anti-tau-120000205.html
    Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
    Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
    finance.yahoo.com
  • D
    Dan
    $AMD conversation
    I expect that we will get a very nice lift after earnings. Concerned that the recent drop offs of $INTC and drag of $MU might dampen the bounce. INTC remains a puzzle. If you read the reports, the troubles were known internally at least. We investors in the dark.

    Pleased with Elon's approach to SEC matters and still view $TSLA as a good speculative pick. $SNAP and Evan continue to impress as business model and user growth continues.

    $TVIX and $GUSH may be so depressed it might be time to look at again. Losses significant.

    $BIIB very happy with Biogen as a long term large cap pharma pick, Bought at the bottom and see it as a 8 month hold for 12%-20%. Pharma can be fickle as we know.

    Sharing because it may be of help to you.

    Ring a Ding Ding!!
  • A
    AIKIDO
    AMRN Vascepa’s plaques reduced much more than $BIIB for Alzheimer’s, Mayo Clinic’s
  • T
    TommyA
    $ARFXF conversation
    �Biogen’s product Aducanumab is likely to be “first in class” therapy but has deficits in safety and efficacy on which PMN310 can
    improve, creating “best in class” therapy. Aducanumab is likely to be approved in 2021. $BIIB https://www.bizjournals.com/boston/news/2018/07/06/biogen-shares-leap-as-alzheimers-drug-shows.html?ana=yahoo&yptr=yahoo ....